Payment overview · 2025
General Payments
$450.82
14 reported records · 8 companies
Healthcare provider profile · identity verified
Jesse Bone, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MONTICELLO, AR · NPI 1770039752
Verified facts
What the public records show
CMS Open Payments records show Jesse Bone, CNP received $450.82 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $160.74 | 35.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.67 | 21.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $94.73 | 21.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.88 | 6.2% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.97 | 4.7% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $17.26 | 3.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.12 | 3.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.45 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $450.82 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $103.69 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $103.69 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $97.67 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $94.73 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.05 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 24 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 299 | 75 |
| Gabapentin | Gabapentin | 226 | 51 |
| Metformin Hcl | Metformin Hcl | 187 | 49 |
| Lisinopril | Lisinopril | 166 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 35 |
| Losartan Potassium | Losartan Potassium | 156 | 40 |
| Simvastatin | Simvastatin | 150 | 37 |
| Omeprazole | Omeprazole | 147 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 37 |
| Ozempic | Semaglutide | 119 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 41 |
| Alendronate Sodium | Alendronate Sodium | 102 | 26 |
| Furosemide | Furosemide | 89 | 20 |
| Glipizide | Glipizide | 88 | 15 |
| Tramadol Hcl | Tramadol Hcl | 87 | 16 |
| Meloxicam | Meloxicam | 83 | 21 |
| Carvedilol | Carvedilol | 82 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 12 |
| Potassium Chloride | Potassium Chloride | 76 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 25 |
| Trazodone Hcl | Trazodone Hcl | 65 | 14 |
| Bupropion Xl | Bupropion Hcl | 60 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 59 | 13 |
| Nifedipine Er | Nifedipine | 58 | 11 |
| Azithromycin | Azithromycin | 56 | 45 |
| Glimepiride | Glimepiride | 55 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 14 |
| Glipizide Er | Glipizide | 54 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 16 |
| Prednisone | Prednisone | 50 | 37 |
| Methylprednisolone | Methylprednisolone | 49 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 14 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | suppressed |
| Eliquis | Apixaban | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 13 |
| Famotidine | Famotidine | 45 | suppressed |
| Celecoxib | Celecoxib | 44 | 13 |
| Meclizine Hcl | Meclizine Hcl | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Allopurinol | Allopurinol | 38 | 11 |
| Amoxicillin | Amoxicillin | 37 | 32 |
| Topiramate | Topiramate | 37 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 36 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 12 |
| Alprazolam | Alprazolam | 35 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 27 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Trulance | Plecanatide | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Indomethacin | Indomethacin | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 12 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Austedo | Deutetrabenazine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $450.82 · 14 records | ABBVIE INC. | APTIMA, AUSTEDO XR, BREZTRI, CAPLYTA, FARXIGA, MOUNJARO, Ozempic, QULIPTA, REXULTI, THINPREP 2000 PROCESSOR, UBRELVY, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error